Piedra PA - Search Results

1

Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.

Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, Hui H, Zhang L, Siegel D, Yang H, Saunders O, Boojamra C, Lee G, Samuel D, Babaoglu K, Carey A, Gilbert BE, Piedra PA, Strickley R, Iwata Q, Hayes J, Stray K, Kinkade A, Theodore D, Jordan R, Desai M, Cihlar T. Mackman RL, et al. Among authors: piedra pa. J Med Chem. 2015 Feb 26;58(4):1630-43. doi: 10.1021/jm5017768. Epub 2015 Jan 27. J Med Chem. 2015. PMID: 25574686 Clinical Trial.

2

High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection.

Englund JA, Piedra PA, Jefferson LS, Wilson SZ, Taber LH, Gilbert BE. Englund JA, et al. Among authors: piedra pa. J Pediatr. 1990 Aug;117(2 Pt 1):313-20. doi: 10.1016/s0022-3476(05)80554-2. J Pediatr. 1990. PMID: 2380833

3

High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection.

Englund JA, Piedra PA, Ahn YM, Gilbert BE, Hiatt P. Englund JA, et al. Among authors: piedra pa. J Pediatr. 1994 Oct;125(4):635-41. doi: 10.1016/s0022-3476(94)70026-5. J Pediatr. 1994. PMID: 7931890 Clinical Trial.

4

Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.

Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE Jr, Piedra PA, Gilbert BE. Zeitlin L, et al. Among authors: piedra pa. MAbs. 2013 Mar-Apr;5(2):263-9. doi: 10.4161/mabs.23281. Epub 2013 Feb 8. MAbs. 2013. PMID: 23396091 Free PMC article.

5

Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.

Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A. Kim E, et al. Among authors: piedra pa. J Virol. 2014 May;88(9):5100-8. doi: 10.1128/JVI.03194-13. Epub 2014 Feb 26. J Virol. 2014. PMID: 24574396 Free PMC article.

6

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.

Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L. Hiatt A, et al. Among authors: piedra pa. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7. Proc Natl Acad Sci U S A. 2014. PMID: 24711420 Free PMC article.

7

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.

Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E. Detalle L, et al. Among authors: piedra pa. Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. doi: 10.1128/AAC.01802-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26438495 Free PMC article.

8

GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.

Perron M, Stray K, Kinkade A, Theodore D, Lee G, Eisenberg E, Sangi M, Gilbert BE, Jordan R, Piedra PA, Toms GL, Mackman R, Cihlar T. Perron M, et al. Among authors: piedra pa. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1264-73. doi: 10.1128/AAC.01497-15. Antimicrob Agents Chemother. 2015. PMID: 26666922 Free PMC article.

9

A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.

Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JCG, Moin SM, Graham BS, Piedra PA, Moore ML. Rostad CA, et al. Among authors: piedra pa. J Virol. 2016 Jul 27;90(16):7508-7518. doi: 10.1128/JVI.00012-16. Print 2016 Aug 15. J Virol. 2016. PMID: 27279612 Free PMC article.

10

Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.

Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G. Gilbert BE, et al. Among authors: piedra pa. Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30. Vaccine. 2018. PMID: 30389195

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

268 results

Search Page